Table of Contents
1. Executive Summary
2. Cancer Highlights
3. Methodology
4. Table of Contents
- 4.1 List of boxes
- 4.2 List of tables
- 4.3 Appendices
5. Introduction
- 5.1 Current Treatment Strategies
- 5.2 Disease Definition
- 5.3 Etiology & Pathophysiology
- 5.4 Prognosis
- 5.5 Epidemiology
6. Progress in current treatment strategies
- 6.1 Docetaxel
- 6.2 Vinorelbine
- 6.3 Gemcitabine
- 6.4 Paclitaxel
- 6.5 Pemetrexed
- 6.6 Gefitinib
- 6.7 Erlotinib
- 6.8 Bevacizumab
7. Key Therapeutic Strategies
- 7.1 Apoptosis
- 7.2 Protein Kinase Inhibition - Antiangiogenesis and Antivascular Agents
- 7.2.1 EGFR and VEGFR as target
- 7.3 Immunotherapy
8. Competitive Landscape in NSCLC Drug Development: The Late Stage Pipeline
- 8.1 Protein Kinase Inhibitors
- 8.2 Apoptotic Inducers
- 8.3 Immunotherapy
- 8.4 Other Therapeutic Strategies
9. Disclaimer
- 9.1 Liability
- 9.2 Completeness
10. Appendix 1. Treatment Guide Lines*
11. Appendix 2 Progress Profiles on Approved Drugs
- 11.1 Docetaxel
- 11.2 Vinorelbine
- 11.3 Gemcitabine
- 11.4 Paclitaxel
- 11.5 Pemetrexed
- 11.6 Gefitinib
- 11.7 Erlotinib
12. Drug Index
13. Company Index
4.1 List of boxes
- Box 1: Quick Facts - Docetaxel
- Box 2: Scientific Data on Docetaxel
- Box 3: Quick Facts - Vinorelbine
- Box 4: Scientific Data on Vinorelbine
- Box 5: Quick Facts - Gemcitabine
- Box 6: Scientific Data on gemcitabine
- Box 7: The PIONEER clinical trial
- Box 8: Quick Facts - Pemetrexed
- Box 9: Scientific Data on Pemetrexed
- Box 10: Quick Facts - Gefitinib
- Box 11: Scientific Data on Gefitinib
- Box 12: Expert comment
- Box 13: Quick Facts - Erlotinib
4.2 List of tables
- Table 1: Chemotherapeutic Drugs for Treatment of NSCLC
- Table 2: Clinical Studies of NSCLC Patients With EGFR Mutations
- Table 3: Progress on Bevacizumab
- Table 4: Near Term Approved Drugs for the Treatment of NSCLC
- Table 5: Chemotherapy Drugs off Patent
- Table 6: Generalized Illustration, Depicting the Key Elements Involved in
the Apoptotic Pathways.
- Table 7: VTA Agents Under Development
- Table 8: EGFR or VEGFR Inhibitors
- Table 9: FMS-Like Tyrosine Kinases and Their Synonyms
- Table 10: Fms-related Tyrosine Kinase Targets in Development
- Table 11: Protein Kinase Targets in Clinical Trials for Lung Cancer
- Table 12: Cancer Immunotherapy Strategies
- Table 13: Progress on Lapatinib
- Table 14: Progress on ZD6474
- Table 15: Progress on Trastuzumab
- Table 16: Progress on Panitumumab
- Table 17: Progress on Cetuximab
- Table 18: Progress on Neovastat
- Table 19: Progress on Affinitak
- Table 20: Progress on Sorafenib
- Table 21: Progress on Canfosfamide
- Table 22: Progress on Exisulind
- Table 23: Progress on Genasense
- Table 24: Progress on Bexarotene
- Table 25: Progress on IGN101
- Table 26: Progress on CPG 7909
- Table 27: Progress on Vinflunine
- Table 28: Progress on Talabostat
- Table 29: Ongoing Studies
- Table 30: Progress on Xcytrin
- Table 31: Progress on Tirapazamine
- Table 32: Progress on Efaproxiral
4.3 Appendices
- 10. Appendix 1. Treatment Guide Lines*
- 11. Appendix 2. Progress Profiles on Approved Drugs
|
Related Report
|
View Cart
